Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

8:33

Headlines

Research Papers

Google DeepMind Releases Agentic Cheminformatics Tools for Google Antigravity

Google DeepMind has introduced Cheminformatics Skills for its Google Antigravity platform to automate drug discovery workflows and propose novel candidate molecules.

FTMQ SI, written by our newsroom1 view

Share
Picture: DeepMind Research News

DeepMind Research News and Google DeepMind reported that new Cheminformatics Skills have been introduced for Google Antigravity to accelerate drug discovery workflows. The Chenab Times reported that the update enhances drug discovery using artificial intelligence agents. Designing new medicines typically takes multiple days for a single iteration, but the new system automates compound searching and candidate proposals, according to DeepMind Research News. [1][2][4]

The project was authored by Zoi Tsangalidou, Ruijie (Kelly) Zhang, Sukhdeep Singh, and Michael V. LeVine, according to DeepMind Research News. Using real-world lung cancer treatments, the AI agent searches through thousands of compounds, carries out matched molecular pair analysis, and proposes novel rigidified macrocycles to synthesize. Remio reported that the update brings these research steps into a single unified workflow. [1][3]

Google Antigravity is a software development platform where artificial intelligence agents write, run, and test code autonomously. It was launched on November 18, 2025, alongside the Gemini 3 model as an integrated development environment based on Visual Studio Code. In May 2026, Google added Antigravity 2.0 as a standalone desktop application featuring a command-line interface and software development kit. [5]

Antigravity provides direct model access without extra web-access retrieval or additional safety layers found in standard consumer interfaces. The platform supports multiple models including Gemini 3.1 Pro, Gemini 3 Flash, Claude Sonnet 4.6, Claude Opus 4.6, and gpt-oss-120b. [7]

Share

In short

  • Google DeepMind introduced Cheminformatics Skills for Google Antigravity to accelerate drug discovery workflows.
  • The AI system can search thousands of compounds and propose novel rigidified macrocycles for lung cancer treatments.
  • Google Antigravity was originally launched on November 18, 2025, alongside Gemini 3.
  • The platform supports AI models including Gemini 3.1 Pro, Gemini 3 Flash, Claude 4.6 variants, and gpt-oss-120b.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]Agentic cheminformatics with Google AntigravityDeepMind Research News, 14d ago (the report this story comes from)
  2. [2]Agentic Cheminformatics with Google AntigravityGoogle DeepMind, 14d ago
  3. [3]Agentic cheminformatics with Google Antigravity brings research steps into one workflowremio, 12d ago
  4. [4]Google DeepMind Enhances Drug Discovery with AI-Powered Agentic CheminformaticsThe Chenab Times, 13d ago

Background

  1. [5]Google Antigravity on Wikipedia
  2. [6]Maximum common induced subgraph on Wikipedia
  3. [7]Google Antigravity on Grokipedia

Our newsroom writes these reports with the help of software, from the 7 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Research Papers

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.